Proposed Classes Ask To Combine Janssen Antitrust Suits

Four proposed classes suing Janssen Biotech for allegedly using sham patent litigation to keep a generic version of its prostate cancer drug off the market want a Virginia federal court to...

Already a subscriber? Click here to view full article